{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T16:46:19Z","timestamp":1776789979914,"version":"3.51.2"},"reference-count":30,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Azole resistance is an emerging increasing problem in\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Aspergillus fumigatus<\/jats:named-content>\n            that results in treatment failure. Alternative treatments may improve the therapeutic outcome in patients with azole-resistant invasive aspergillosis (IA). Little is known about the\n            <jats:italic>in vivo<\/jats:italic>\n            efficacy of the echinocandin anidulafungin (AFG) in IA. The\n            <jats:italic>in vivo<\/jats:italic>\n            efficacy of 2.5, 5, 10, and 20 mg\/kg of body weight AFG was assessed against two clinical\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Aspergillus fumigatus<\/jats:named-content>\n            isolates with identical AFG minimum effective concentrations (MECs; 0.03 mg\/liter) in a murine model of IA: a wild-type voriconazole (VCZ)-susceptible (VCZ\n            <jats:sup>s<\/jats:sup>\n            )\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">A. fumigatus<\/jats:named-content>\n            isolate (AZN 8196) and a VCZ-resistant (VCZ\n            <jats:sup>r<\/jats:sup>\n            )\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">A. fumigatus<\/jats:named-content>\n            isolate (V52-35) harboring the TR\n            <jats:sub>34<\/jats:sub>\n            \/L98H resistance mechanism (substitution at codon L98 in combination with a 34-bp tandem repeat in the promoter region of the\n            <jats:italic>CYP51A<\/jats:italic>\n            gene). The pharmacokinetics of AFG were also assessed for each dose. Increasing doses increased survival for both isolates in a manner dependent on the AFG dose level (\n            <jats:italic>R<\/jats:italic>\n            <jats:sup>2<\/jats:sup>\n            = 0.99 and 0.95, respectively) up to a maximum of 72.7% and 45.45% for the VCZ\n            <jats:sup>s<\/jats:sup>\n            and VCZ\n            <jats:sup>r<\/jats:sup>\n            isolates, respectively. The area under the concentration-time curve (AUC) correlated significantly with the dose in a linear fashion over the entire dosing range (\n            <jats:italic>R<\/jats:italic>\n            <jats:sup>2<\/jats:sup>\n            = 0.86). The Hill equation with a variable slope fitted the relationship between the 24-h AUC\/MEC ratio and 14-day survival well (\n            <jats:italic>R<\/jats:italic>\n            <jats:sup>2<\/jats:sup>\n            = 0.87;\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.05). The 50% effective AUC\/MEC for total AFG was 126.5 (95% confidence interval, 79.09 to 202.03). AFG treatment improved the survival of mice in a dose-dependent manner; however, a maximal response was not achieved with either isolate even in those treated with the highest AFG dose.\n          <\/jats:p>","DOI":"10.1128\/aac.01430-12","type":"journal-article","created":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:17:28Z","timestamp":1351729048000},"page":"303-308","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":18,"title":["Pharmacodynamics of Anidulafungin against Clinical Aspergillus fumigatus Isolates in a Nonneutropenic Murine Model of Disseminated Aspergillosis"],"prefix":"10.1128","volume":"57","author":[{"given":"Seyedmojtaba","family":"Seyedmousavi","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands"},{"name":"Nijmegen Institute for Infection, Inflammation and Immunity, Nijmegen, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger J. M.","family":"Br\u00fcggemann","sequence":"additional","affiliation":[{"name":"Nijmegen Institute for Infection, Inflammation and Immunity, Nijmegen, the Netherlands"},{"name":"Department of Pharmacy, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willem J. G.","family":"Melchers","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands"},{"name":"Nijmegen Institute for Infection, Inflammation and Immunity, Nijmegen, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul E.","family":"Verweij","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands"},{"name":"Nijmegen Institute for Infection, Inflammation and Immunity, Nijmegen, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan W.","family":"Mouton","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands"},{"name":"Nijmegen Institute for Infection, Inflammation and Immunity, Nijmegen, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/23.3.608"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5520(02)00035-1"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200401-093OC"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020191"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/525258"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr443"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2006.08.017"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00185-11"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050219"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05394-11"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1710.110226"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2009.09.002"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc061720"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1507.090043"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1080\/13693780802545600"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1086\/597465"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12281-010-0018-6"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-011-0216-6"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1086\/423389"},{"key":"e_1_3_2_21_2","unstructured":"Rodriguez-TudelaJL\nArendrupMC\nArikanS\nBarchiesiF\nBilleJCE\nCuenca-EstrellaEMM\nDannaouiEE\nDenningDW\nDonnellyJP\nFegelerW\nLass-Fl\u00f6rlC\nMooreC\nRichardsonM\nGaustadP\nSchmalreckA\nVelegrakiAA\nVerweijP. 2008. EUCAST definitive document E.DEF 9.1: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds. Subcommittee on Antifungal Susceptibility Testing (AFST) of ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST) London United Kingdom."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00931-09"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00606-10"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2011.08.001"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks402"},{"key":"e_1_3_2_26_2","volume-title":"Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., abstr. M1536","author":"Mavridou E","year":"2011","unstructured":"MavridouE MeletiadisJ JancuraP AbbasS ArendrupMC MelchersWG MoutonJW VerweijPE. 2011. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., abstr. M1536, Chicago, IL."},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.12.5058-5068.2005"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01584-09"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00507-06"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01556-08"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir023"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01430-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01430-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:29:23Z","timestamp":1645482563000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01430-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.1128\/AAC.01430-12"],"URL":"https:\/\/doi.org\/10.1128\/aac.01430-12","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1]]},"assertion":[{"value":"2012-07-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-10-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-12-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}